Maridebart cafraglutide showed significant weight loss in adults with obesity, with or without type 2 diabetes, in a phase 2 trial. The drug combines GLP-1 receptor agonism with GIP receptor ...

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...

It’s that time of year when we rethink our lives, our choices, and for many of us, our weight. Losing those extra kilos is often on our minds, but how many of us find it hard to lose those pounds year ...

Pfizer recently began a phase 3 trial of weekly PF’3944. (iStock / Getty Images Plus) Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor ...